S Vamvakas
Overview
Explore the profile of S Vamvakas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
832
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Isaac M, Vamvakas S
J Prev Alzheimers Dis
. 2017 Nov;
4(3):134-135.
PMID: 29182702
No abstract available.
2.
Isaac M, Vamvakas S, Isaac M
Lancet Neurol
. 2017 Jul;
16(8):580-581.
PMID: 28721916
No abstract available.
3.
Martinalbo J, Bowen D, Camarero J, Chapelin M, Demolis P, Foggi P, et al.
Ann Oncol
. 2015 Oct;
27(1):96-105.
PMID: 26487583
Patient access to new cancer drugs in the EU involves centralised licensing decisions by regulators as well as reimbursement recommendations in the context of national healthcare systems. Differences in assessment...
4.
Eichler H, Baird L, Barker R, Bloechl-Daum B, Borlum-Kristensen F, Brown J, et al.
Clin Pharmacol Ther
. 2015 Feb;
97(3):234-46.
PMID: 25669457
The concept of adaptive licensing (AL) has met with considerable interest. Yet some remain skeptical about its feasibility. Others argue that the focus and name of AL should be broadened....
5.
Romero K, Ito K, Rogers J, Polhamus D, Qiu R, Stephenson D, et al.
Clin Pharmacol Ther
. 2015 Feb;
97(3):210-4.
PMID: 25669145
Failures in trials for Alzheimer's disease (AD) may be attributable to inadequate dosing, population selection, drug inefficacy, or insufficient design optimization. The Coalition Against Major Diseases (CAMD) was formed in...
6.
Ehmann F, Papaluca Amati M, Salmonson T, Posch M, Vamvakas S, Hemmings R, et al.
Clin Pharmacol Ther
. 2013 Apr;
93(5):425-32.
PMID: 23549149
This article analyzes the role of regulatory authorities in facilitating innovation in the pharmaceutical sector. We describe how regulators are expanding their role to be not only gatekeepers but also...
7.
Abellan van Kan G, Cderbaum J, Cesari M, Dahinden P, Fariello R, Fielding R, et al.
J Nutr Health Aging
. 2011 Dec;
15(10):834-46.
PMID: 22159770
No abstract available.
8.
Vamvakas S, Dekant W, Henschler D
Toxicol In Vitro
. 2010 Aug;
3(2):151-6.
PMID: 20702313
The genotoxicity of the glutathione S-conjugates S-(12-dichlorovinyl)glutathione (DCVG), S-(1,2,2-trichlorovinyl)glutathione (TCVG), S-(1,2,3,4,4-pentachlorobutadienyl)glutathione (PCBG) and S-(2-chloroethyl)glutathione (CEG) was investigated in LLC-PK1, a cultured line of porcine kidney cells that exhibits many properties...
9.
Mullner M, Vamvakas S, Rietschel M, van Zwieten-Boot B
Int J Clin Pharmacol Ther
. 2007 Oct;
45(9):477-84.
PMID: 17907590
Objective: There is concern that patients included in trials do not represent the true patient population and women in particular may selectively be excluded. We looked at trial data submitted...
10.
Vamvakas S, Bruning T, Bolt H, Henschler D, Ulm K
J Cancer Res Clin Oncol
. 2000 Mar;
126(3):178-80.
PMID: 10741913
No abstract available.